Telomir Pharmaceuticals completes IPO of 1M shares at $7.00, raising $7M gross

Telomir Pharmaceuticals, Inc.

Priced 1,000,000 shares at $7.00; gross proceeds $7M. Shares began trading on Nasdaq Feb 9 under TELO.
Underwriters granted 45-day option to purchase up to 150,000 additional shares at IPO price.
Representative's warrants issued to Kingswood for 50,000 shares at $7.00, exercisable after 6-month lock.
Kingswood Investments acted as sole book-running manager; underwriting discount 7% of gross proceeds.
Proceeds to fund development of Telomir-1, a pre-clinical small molecule for age reversal.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Telomir Pharmaceuticals, Inc. entered into Underwriting Agreement with Kingswood Investments, division of Kingswood Capital Partners, LLC valued at $7,000,000 (effective 2024-02-08).

Action: entry
Agreement: underwriting
Counterparty: Kingswood Investments, division of Kingswood Capital Partners, LLC
Value: $7,000,000
Effective: 2024-02-08

Exact text from the filing

On February 8, 2024, Telomir Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement with Kingswood Investments, division of Kingswood Capital Partners, LLC (“Kingswood”) on behalf of itself and as representative of the underwriters named therein (the “Underwriting Agreement”), pursuant to which the Company issued and sold, in an underwritten public offering (the “Public Offering”), 1,000,000 shares of common stock, no par value (“Common Stock”).

View on SEC.gov

283 material agreements filed in the last 30 days. Browse all material agreements →

Telomir Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-006094

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.